Ventilation Associated Pneumonia and Covid-19

Completed

• Conditions: COVID-19; SARS-CoV2 Infection; Ventilator Associated Pneumonia; Ards

• Registration Number: NCT05089968
• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Brief Summary

In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-24
• Primary Completion: 2021-01-08
• Study Completion: 2021-01-08
• Status Verified: 2021-10
• Study First Submitted: 2021-10-21
• Study First Submitted QC: 2021-10-21
• Last Update Submitted: 2021-10-21
• Study First Posted: 2021-10-22
• Last Update Posted: 2021-10-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 268

Inclusion Criteria

• Age > 18 years
• Positive SARS-Cov-2 polymerase chain reaction (PCR)
• healthcare associated pneumonia

Exclusion Criteria : Patient opposition to participate to the study

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
VAP ecological difference between the first and second waves of COVID	January 2020 to January 2021	Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2

Secondary Outcome Measures

Name	Time	Method
proportion of fungal co-infections	January 2020 to January 2021	Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave
Mortality	Day 28	proportion of patients deceased at day 28
proportion of patients treated with corticosteroid therapy	Day 28	proportion of patients treated with corticosteroid therapy
antiviral treatment	Day 28	proportion of patients treated with antiviral treatment
duration of mechanical ventilation	Day 28	Number of days under mechanical ventilations
probabilistic antibiotic therapy at admission	Day 1	probabilistic antibiotic therapy prescribed at admission
number of days of organ failure	Day 28	number of days between first organ failure and no organ failure (discharge from intensive care)

Trial Locations

Locations (1)

CHU de Nîmes - Hôpital Universitaire Carémeau; 🇫🇷 Nîmes Cedex 09, France